IL161697A0 - Process for preparing quick dissolving, high loading ribavirin compositions - Google Patents

Process for preparing quick dissolving, high loading ribavirin compositions

Info

Publication number
IL161697A0
IL161697A0 IL16169702A IL16169702A IL161697A0 IL 161697 A0 IL161697 A0 IL 161697A0 IL 16169702 A IL16169702 A IL 16169702A IL 16169702 A IL16169702 A IL 16169702A IL 161697 A0 IL161697 A0 IL 161697A0
Authority
IL
Israel
Prior art keywords
high loading
quick dissolving
preparing quick
ribavirin compositions
loading ribavirin
Prior art date
Application number
IL16169702A
Other languages
English (en)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL161697A0 publication Critical patent/IL161697A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL16169702A 2001-11-02 2002-10-31 Process for preparing quick dissolving, high loading ribavirin compositions IL161697A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33685301P 2001-11-02 2001-11-02
PCT/US2002/034899 WO2003039517A1 (en) 2001-11-02 2002-10-31 Process for preparing quick dissolving, high loading ribavirin compositions

Publications (1)

Publication Number Publication Date
IL161697A0 true IL161697A0 (en) 2004-09-27

Family

ID=23317956

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16169702A IL161697A0 (en) 2001-11-02 2002-10-31 Process for preparing quick dissolving, high loading ribavirin compositions

Country Status (16)

Country Link
US (1) US20030104050A1 (xx)
EP (1) EP1443911A1 (xx)
JP (1) JP2005511587A (xx)
KR (1) KR20050042035A (xx)
CN (1) CN1585631A (xx)
AU (1) AU2002350082B9 (xx)
BR (1) BR0213861A (xx)
CA (1) CA2465159A1 (xx)
HR (1) HRP20040384A2 (xx)
HU (1) HUP0402364A2 (xx)
IL (1) IL161697A0 (xx)
MX (1) MXPA04004181A (xx)
NO (1) NO20042143L (xx)
PL (1) PL368550A1 (xx)
RU (1) RU2004116821A (xx)
WO (1) WO2003039517A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
GEP20094681B (en) * 2004-05-24 2009-05-10 Nycomed Pharma As Agglomeration of calcium-containing compound obtained by roller compaction
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US7723310B2 (en) * 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
US20060110479A1 (en) * 2004-11-24 2006-05-25 Mitra Shankar K Natural composition for curing hepatitis-B, methods for making the same and pharmaceutical formulations thereof
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
MX2009006699A (es) * 2006-12-21 2009-06-30 Mallinckrodt Inc Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
US8202996B2 (en) * 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2010062996A2 (en) * 2008-11-28 2010-06-03 Adamas Pharmaceuticals, Inc. Ribavirin composition
EP2295037A1 (en) 2009-09-11 2011-03-16 Ratiopharm GmbH Pharmaceutical formulation containing Ribavirin
CA2801896C (en) * 2010-06-08 2015-08-11 Laboratorio De Diagnostico Gam, S.A. Oral veterinarian composition for salmonids comprising 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide and use thereof in the treatment of infectious anemia in salmonids
CN107847608A (zh) * 2015-06-09 2018-03-27 联邦科学和工业研究组织 聚阴离子聚合物和抗病毒药物的抗病毒共轭物
CN106806345B (zh) * 2015-11-27 2020-10-13 北京科信必成医药科技发展有限公司 一种利巴韦林掩味颗粒及其制备方法
CN108464972A (zh) * 2018-07-02 2018-08-31 福州大学 一种含有斯诺普利的抗肺动脉高压口服片剂及其制备方法
CA3194665A1 (en) 2020-10-05 2022-04-14 Jia-Ning Xiang Modified release compositions of a gamma-hydroxybutyric acid derivative
CN113304114B (zh) * 2021-06-08 2022-06-10 药大制药有限公司 一种利巴韦林颗粒及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3277520A (en) * 1963-06-18 1966-10-11 Fuji Denki Kogyo Kabushiki Kai Method and apparatus for making spherical granules
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3976545A (en) * 1973-03-12 1976-08-24 Icn Pharmaceuticals, Inc. 1,2,4-Triazol E-3-carboxamides as antiviral agents
US3948885A (en) * 1973-03-19 1976-04-06 Icn Pharmaceuticals, Inc. 5-Hydroxyl-1,2,3-triazole-4-carboxamide nucleoside
US4138547A (en) * 1977-12-22 1979-02-06 Icn Pharmaceuticals, Inc. Process for preparing 1,2,4-triazole nucleosides
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5405837A (en) * 1993-05-18 1995-04-11 Indiana University Foundation Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6150337A (en) * 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
PL187107B1 (pl) * 1996-10-16 2004-05-31 Icn Pharmaceuticals L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
EP0991415B1 (en) * 1997-12-22 2003-03-12 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets

Also Published As

Publication number Publication date
KR20050042035A (ko) 2005-05-04
RU2004116821A (ru) 2005-04-20
CA2465159A1 (en) 2003-05-15
CN1585631A (zh) 2005-02-23
EP1443911A1 (en) 2004-08-11
BR0213861A (pt) 2004-12-21
US20030104050A1 (en) 2003-06-05
AU2002350082B9 (en) 2006-08-31
HRP20040384A2 (en) 2005-08-31
NO20042143L (no) 2004-05-25
AU2002350082B2 (en) 2006-07-20
HUP0402364A2 (hu) 2005-02-28
WO2003039517A1 (en) 2003-05-15
MXPA04004181A (es) 2005-01-25
PL368550A1 (en) 2005-04-04
JP2005511587A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
IL161697A0 (en) Process for preparing quick dissolving, high loading ribavirin compositions
HK1078087A1 (en) Process for the preparation of (s,s)-cis-2-benzhydryl-3- benzylaminoquinuclidine
IL183568A (en) Process for making 7,8-dihydro-5 h-patridine-6-onh
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
HUP0402264A3 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
HK1089768A1 (en) Indolone-acetamide derivatives, processes for preparing them and their uses
PL1561754T3 (pl) Sposób wytwarzania związków kompleksowych 1,2-diaminocykloheksan-platyna(II)
EG23299A (en) Process for preparing 1-octene.
HK1078863A1 (en) Process for preparing (s)-pantoprazole
IL156219A0 (en) Process for preparing stabilized compositions based on polyamide
IL159994A0 (en) Process for preparing 4-aminodiphenylamine
IL166698A0 (en) Process for preparing paste-extruded sulfonamide compositions
ZA200402472B (en) Method for preparing benzenesulfonyl compounds.
MY137678A (en) Process for preparing formaldehyde
ZA200408857B (en) Low isoflavones, high saponins soy protein productand process for producing the same.
HK1086008A1 (en) Process for preparing substituted 5-amino-pyrazolo-Ä4,3-eÜ-1,2,4-triazoloÄ1,5-cÜpyrimidines
SG115596A1 (en) Process for preparing tert-butanol
ZA200108623B (en) Process for preparing imidachloprid.
SI1888537T1 (sl) Postopek priprave 4-((1,6-dihidro-6-okso-2-pirimidinil)amino benzonitrila
PL364836A1 (en) Predispersions, compositions therefore, and processes for preparing same
TW484471U (en) Extension sideboard structure for round saw machine
ZA200305338B (en) An improved process for preparing pure ondansetron hydrochloride dihydrate.
AP2005003229A0 (en) Process for preparing of paclitaxel.
AU2003234352A1 (en) Process for preparing apigenin-7-o-%a-d-glucuronide from clerodendron trichotomum folium
PL371913A1 (en) Method for synthesizing beta-l-fluoro-2',3'-dideoxy-didehydcytidine (beta-l-fd4c)